Regulatory decisions diverge over aducanumab for Alzheimer's disease

BMJ. 2022 Jan 28:376:e069780. doi: 10.1136/bmj-2021-069780.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Alzheimer Disease*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Decision Making*
  • Drug and Narcotic Control*
  • Humans
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal, Humanized
  • aducanumab